Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis boosts 2019...

    Novartis boosts 2019 forecasts as Cosentyx, Zolgensma shine

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-27T09:45:26+05:30  |  Updated On 27 Oct 2019 9:45 AM IST
    Novartis boosts 2019 forecasts as Cosentyx, Zolgensma shine

    Zolgensma, the $2.1 million-per-patient treatment for spinal muscular atrophy, posted $160 million in sales. Novartis now anticipated approval in Europe and Japan only in 2020, not this year as previously expected.


    New Delhi: Novartis on Tuesday boosted its full-year targets, as sales of medicines including psoriasis drug Cosentyx and gene therapy Zolgensma helped the Swiss drugmaker surpass analysts' third-quarter expectations.


    Sales are now seen growing at a high single-digit percentage rate at constant currencies, from the mid-to-high single-digit rate forecast from July. Core operating income is now seen growing at a mid- to a high-teen rate, up from low double-digit to mid-teen percentages.


    Third-quarter core net income rose 17% to $3.2 billion. Sales were $12.2 billion, well beyond the $11.7 billion average in a Refinitiv poll.


    The shares were seen rising more than 2%, according to pre-market indicators provided by Bank Julius Baer.


    Chief Executive Vas Narasimhan has now raised targets for the third time this year, matching cross-town rival Roche's guidance moves, amid his push to expand into gene therapy and advanced cancer treatments.


    Zolgensma, the $2.1 million-per-patient treatment for spinal muscular atrophy, posted $160 million in sales. Novartis now anticipated approval in Europe and Japan only in 2020, not this year as previously expected.


    Read Also: Novartis Jakavi meets primary endpoint in a study of acute graft-versus-host disease


    Narasimhan said the issues that pushed back Japanese and European decisions on Zolgensma centred on regulators' questions about manufacturing, not about data manipulation surrounding its U.S. approval that has spurred a U.S. Food and Drug Administration investigation.


    "For both regulators, the written questions have not related specifically to any of the data topics we've had recently," Narasimhan said. "They were primarily related to the manufacturing issues, as well as interest in doing additional inspections of our various manufacturing facilities."


    By John Miller


    Read Also: Novartis gets USFDA nod for Beovu for wet Age-related Macular Degeneration

    2019 drug salesCosentyxFood and Drug Administrationgene therapyNovartisnovartis salespsoriasis drugskin drugsspinal muscular atrophyUSFDAUSFDA approvalZolgensma
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok